Recent News

• 09.15.2025 - Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
• 09.15.2025 - Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
• 09.09.2025 - Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
• 09.09.2025 - Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
• 09.02.2025 - Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
• 09.02.2025 - Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
• 08.29.2025 - Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
• 08.29.2025 - Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
• 08.27.2025 - Emergent BioSolutions to Participate in Upcoming Investor Conferences
• 08.27.2025 - Emergent BioSolutions to Participate in Upcoming Investor Conferences

Recent Filings

• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 8-K Current report
• 09.05.2025 - 8-K Current report
• 09.05.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 144 Report of proposed sale of securities
• 08.15.2025 - EFFECT Notice of Effectiveness
• 08.13.2025 - CORRESP Correspondence